Stockreport

Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting [Yahoo! Finance]

Artivion, Inc.  (AORT) 
PDF 72% Reduction in All-Cause Mortality and 52% Reduction in Primary Major MAEs when Compared to Current Standard of Care Hemi-arch Procedure ATLANTA Jan. 29, 2024 /PRNe [Read more]